A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

INTEGRA Biosciences Launches the D-ONE Single Channel Pipetting Module for ASSIST PLUS (1166-21)

INTEGRA Biosciences has created the D-ONE single channel pipetting module for hands-free transfers from individual tubes or wells using the ASSIST PLUS pipetting robot.

This system effectively automates tedious tasks such as serial dilutions, sample normalization, hit picking or pipetting of complex plate layouts, increasing productivity and reproducibility in the lab while reducing hands-on time, processing errors and physical strain.

The D-ONE is available in two volume ranges – from 0.5 to 300 μl and 5 to 1250 μl – to ensure optimal pipetting performance across a wide volume range. Each D-ONE module has two separate pipetting channels, using 12.5 and 300 μl or 125 and 1250 μl GripTips for high and low volumes respectively. The D-ONE pipetting module senses the liquid level immediately before aspiration, and is compatible with all INTEGRA GripTips used for benchtop pipetting devices. This avoids the need for special tips, and saves time during program set-up. Combined with a specially designed D-ONE tip deck that can accommodate two tip racks, this allows the ASSIST PLUS to automatically switch between the different GripTips without tedious manual intervention, offering longer walk-away times.

The combination of the D-ONE and ASSIST PLUS ensures accurate and reproducible results every time by successfully automating dilution calculations for normalizations, hit picking without any transcription errors, and master mix preparations for varying sample numbers and volumes. This makes the D-ONE the perfect add-on for labs that want to go beyond the possibilities of multichannel pipetting to access unlimited applications on the ASSIST PLUS.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.
“We are excited to present the first look at the safety and clinical activity of ELVN-001, which we believe supports the potential for ELVN-001 to address the limitations of the available active-site TKIs,” said Helen Collins, M.D., Chief Medical Officer of Enliven. “Across a wide dose range, ELVN-001 demonstrated activity in a heavily pre-treated patient population that includes post-asciminib patients, with a preliminary safety profile consistent with its highly selective design. Not only did all evaluable patients have improved or stable BCR::ABL1 transcript levels, but, importantly, 89% of all patients enrolled remain on study. We believe the initial data demonstrate the potential clinical utility of ELVN-001 for all types of patients, including those that are earlier in the treatment paradigm.”
The partnership is with Health-HavenRx ™, an online pharmacy platform. This partnership enables a new, convenient channel for patients to access POGO Automatic by using their health insurance on Intuity Medical’s e-commerce website at www.GoodtoPogo.com.

By using this website you agree to accept Medical Device News Magazine Privacy Policy